Skip to main content

Table 1 Clinicopatholodical characteristics of patients with HAS and Non-HAS treated with radical gastrectomy

From: The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis

Factors

Before propensity matching

After 1:1propensity matching

After 1:2 propensity matching

Non-HAS

HAS

P value*

Non-HAS

HAS

P value

Non-HAS

HAS

P value

(n = 711)

(n = 73)

n = 72

N = 72

n = 110

n = 55

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

Sex (M/F)

509/202

60/13

0.053

60/12

59/13

0.826

87/23

44/11

0.892

Age (median) (yr))#

59 (24-84)

58 (26-76)

0.720

62 (31-81)

58 (26-76)

0.155

58 (36-80)

60 (26-76)

0.136

 <45

78 (11.0)

7 (9.6)

 

3 (4.2)

7 (9.7)

 

12 (10.9)

5 (9.1)

 

 60>age≥45

278 (39.1)

32 (43.8)

 

26 (36.1)

31 (43.1)

 

50 (45.5)

22 (40.0)

 

 ≥60

355 (49.9)

34 (46.6)

 

43 (59.7)

34 (47.2)

 

48 (43.6)

28 (50.9)

 

Locationa

  

0.364

  

0.640

  

0.785

 U

217 (30.5)

25 (34.2)

 

19 (26.4)

24 (33.3)

 

39 (35.5)

19 (34.5)

 

 M

126 (17.7)

9 (12.3)

 

11 (15.3)

9 (12.5)

 

11 (10.0)

7 (12.7)

 

 L

360 (50.6)

39 (53.4)

 

42 (58.3)

39 (54.2)

 

59 (53.6)

29 (52.7)

 

 T

8 (1.1)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

1 (0.9)

0 (0.0)

 

Surgery type

  

0.584

  

1.000

  

0.445

 PG

9 (1.3)

2 (2.7)

 

0 (0.0)

1 (0.7)

 

1 (0.9)

2 (3.6)

 

 DG

350 (49.2)

39 (53.4)

 

42 (58.3)

40 (56.9)

 

55 (50.0)

30 (54.5)

 

 TG

349 (49.1)

32 (43.8)

 

30 (41.7)

31 (42.4)

 

53 (48.2)

23 (41.8)

 

 TGC

3 (0.4)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

1 (0.9)

0 (0.0)

 

Vascular invasion

  

0.328

  

0.074

  

0.315

 no

325 (45.7)

29 (39.7)

 

18 (25.0)

28 (38.9)

 

49 (44.5)

20 (36.4)

 

 yes

386 (54.3)

44 (60.3)

 

54 (75.0)

44 (61.1)

 

61 (55.5)

35 (63.6)

 

T

  

0.004

  

0.051

  

0.990

 Tis, T0, T1, T2

171 (24.0)

21 (28.8)

 

18 (25.0)

20 (27.8)

 

34 (30.9)

17 (30.9)

 

 T3

260 (36.6)

39 (53.4)

 

26 (36.1)

37 (51.4)

 

51 (46.4)

26 (47.3)

 

 T4

280 (39.4)

13 (17.8)

 

28 (38.9)

15 (20.8)

 

25 (22.7)

12 (21.8)

 

N

  

0.180

  

0.182

  

0.566

 N0

221 (31.1)

11 (15.1)

 

12 (16.7)

11 (15.3)

 

29 (26.4)

11 (20.0)

 

 N1

154 (21.7)

23 (31.5)

 

18 (25.0)

23 (31.9)

 

24 (21.8)

17 (30.9)

 

 N2

143 (20.1)

22 (30.1)

 

14 (19.4)

23 (31.9)

 

30 (27.3)

13 (23.6)

 

 N3

293 (27.1)

17 (23.3)

 

28 (38.9)

15 (20.8)

 

27 (24.5)

14 (25.5)

 

M

     

1.00

  

1.000

 M0

711 (100)

73 (100)

 

69 (95.8)

70 (97.2)

 

109 (99.1)

54 (98.2)

 

 M1

0

0

 

3 (4.2)

2 (2.8)

 

1 (0.9)

1 (1.8)

 

EGFR

  

<0.001

  

0.940

  

0.695

 -

64 (9.0)

2 (2.7)

 

1 (1.4)

2 (2.8)

 

6 (5.5)

2 (3.6)

 

 +

259 (36.4)

6 (8.2)

 

16 (22.2)

7 (9.7)

 

10 (9.1)

7 (12.7)

 

 ++

195 (27.4)

36 (49.3)

 

23 (31.9)

37 (51.4)

 

46 (41.8)

26 (47.3)

 

 +++

193 (27.1)

29 (39.7)

 

32 (44.4)

26 (36.1)

 

48 (43.6)

20 (36.4)

 

Ki-67

  

0.003

  

0.648

  

0.741

 0-25%

65 (9.1)

5 (6.8)

 

3 (4.2)

5 (6.9)

 

10 (9.1)

5 (9.1)

 

 26-50%

168 (23.6)

5 (6.8)

 

10 (13.9)

6 (8.3)

 

12 (10.9)

6 (10.9)

 

 51-75%

208 (29.3)

25 (34.2)

 

18 (25.0)

24 (33.3)

 

41 (37.3)

16 (29.1)

 

 76-100%

270 (38.0)

38 (52.1)

 

41 (56.9)

37 (51.4)

 

47 (42.7)

28 (50.9)

 

CEA (ng/ml)

  

<0.001

  

0.384

  

0.266

 ≤5

575 (80.9)

45 (61.6)

 

49 (68.1)

44 (61.1)

 

77 (70.0)

43 (78.2)

 

 >5

136 (19.1)

28 (38.4)

 

23 (31.9)

28 (38.9)

 

33 (30.0)

12 (21.8)

 

CA199 (u/ml)

  

0.026

  

0.347

  

0.716

 ≤37

604 (85.0)

69 (94.5)

 

65 (90.3)

68 (94.4)

 

105 (95.5)

51 (92.7)

 

 >37

107 (15.0)

4 (5.5)

 

7 (9.7)

4 (5.6)

 

5 (4.5)

4 (7.3)

 

Her-2

  

0.012

  

0.962

  

0.883

 -/+

533 (75.0)

43 (58.9)

 

43 (59.7)

43 (59.7)

 

74 (67.3)

35 (63.6)

 

 +++

54 (7.6)

10 (13.7)

 

10 (13.9)

9 (12.5)

 

10 (9.1)

6 (10.9)

 

 ++

124 (17.4)

20 (27.4)

 

19 (26.4)

20 (27.8)

 

26 (23.6)

14 (25.5)

 

neoadjuvant chemotherapy

  

0.005

  

0.441

  

0.880

 no

628 (88.3)

56 (76.7)

 

52 (72.2)

56 (77.8)

 

93 (84.5)

46 (83.6)

 

 yes

83 (11.7)

17 (23.3)

 

20 (27.8)

16 (22.2)

 

17 (15.5)

9 (16.4)

 
  1. M=male, F=female aDivide the major and minor curvature of the stomach into 3 equal parts, connect their corresponding points, can be divided into upper 1/3(U) middle 1/3 (M), lower 1/3 (L) and the total stomach (T) TG= total gastrectomy DG=distal gastrectomy PG=proximal gastrectomy
  2. TGC=gastrectomy combined with visceral resection * categorical data were using the chi-square test (X ²test), and continuous data were using the Mann-Whitney U test. # median (range), and compared by non-parametric tests
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us